Although no research has divulged the significance of ERCC2 in the prognosis and treatment of breast cancer, ERCC2 mutation was reported to be an independent predictor in bladder cancer patients and a potential marker for chemosensitivity in primary and secondary muscle-invasive bladder cancer patients [38, 39]. This evidence concerns the gene ERCC2 and breast carcinoma.